Key regulators of sensitivity to immunomodulatory drugs in cancer treatment

Immunomodulatory drugs (IMiDs) include thalidomide, lenalidomide, and pomalidomide, which have shown significant efficacy in the treatment of multiple myeloma (MM), myelodysplastic syndrome (MDS) with deletion of chromosome 5q (del(5q)) and other hematological malignancies. IMiDs hijack the CRL4(CRB...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Shichao, Li, Zhiyue, Gao, Shaobing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8180172/
https://www.ncbi.nlm.nih.gov/pubmed/34090534
http://dx.doi.org/10.1186/s40364-021-00297-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8180172/
https://www.ncbi.nlm.nih.gov/pubmed/34090534
http://dx.doi.org/10.1186/s40364-021-00297-6

Ejemplares similares